PHAIT, Inc.

PHAIT aims to intercept lung cancer, the deadliest cancer worldwide, by treating pre-cancer dysplasia with oral Iloprost to reduce lung cancer incidence and death. Iloprost is an immuno-modulator repurposed drug that is currently FDA approved, reimbursed, and routinely used for the treatment of pulmonary arterial hypertension (PAH) and Raynaud’s disease. Consequently, Iloprost is de-risked with proven patient safety and tolerance. Daily doses of a proprietary formulation of oral Iloprost, exclusively licensed from Bayer to be manufactured by PHAIT, will provide the therapeutic breakthrough. Oral Iloprost has demonstrated effectiveness in a published Phase 2a clinical study where patients taking the drug for six months responded significantly with precancerous dysplasia reduced by half: https://aacrjournals.org/cancerpreventionresearch/article/4/6/793/49855/Oral-Iloprost-Improves-Endobronchial-Dysplasia-in?searchresult=1.